Arcutis Biotherapeutics, Inc. (ARQT) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Arcutis Biotherapeutics (ARQT) by buying shares or fractional shares at any major broker, or holding it inside a thematic dermatology or growth-biotech basket. Arcutis is a commercial-stage medical dermatology company built almost entirely around ZORYVE (topical roflumilast), a PDE4 inhibitor now approved across plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. The story is one of fast top-line growth (revenue up about 45% in Q3 2026, with 2026 guidance raised to $535 to $545 million) set against heavy dependence on a single franchise and uneven profits. As of November 20, 2026 the shares closed at $26.64 (market cap about $3.4 billion), down about 8% for the year and 2.5% over twelve months.
ARQT stock price
As of 2026-11-20, Arcutis Biotherapeutics, Inc. (ARQT) last closed at $26.36, down 10.6% over the past year. Over the past 52 weeks it has traded between $19.50 and $34.05.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Arcutis Biotherapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
ARQT key stats
At $26.36 on November 20, 2026, Arcutis Biotherapeutics, Inc. (ARQT) has a market cap of $3.3B and a P/E of 119.8 on trailing earnings (24.1 on forward earnings).
- Market cap
- $3.3B
- P/E (trailing)
- 119.8
- P/E (forward)
- 24.1
- EPS (trailing 12 months)
- $0.22
- Price to book
- 13.6
- Beta
- 1.63
Market cap, P/E and yield are measured at the $26.36 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Arcutis Biotherapeutics, Inc. (ARQT)?
The last two weeks for Arcutis Biotherapeutics, Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ARQT closed at $26.36 on November 20, 2026, down 6.7% over the past five trading days (from $28.26).
Arcutis Biotherapeutics, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Arcutis Biotherapeutics, Inc. (ARQT) latest quarter
Arcutis Biotherapeutics reported revenue of $144 million for Q3 2026, up 45% from a year earlier (Arcutis Biotherapeutics, Nov 4, 2026).
Source: Arcutis Q3 2026 results, Nov 4, 2026. Full earnings breakdown
What does Arcutis Biotherapeutics, Inc. (ARQT) do?
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on medical dermatology. Its business is built around ZORYVE, a topical formulation of roflumilast that inhibits phosphodiesterase type 4 (PDE4), an anti-inflammatory target long used in dermatology. ZORYVE is sold as a cream 0.3% for plaque psoriasis, a foam 0.3% for seborrheic dermatitis, and cream formulations (0.15% and 0.05%) for atopic dermatitis spanning adults down to young children. The pitch to dermatologists is a steroid-free, once-daily topical with a clean tolerability profile that can be used on sensitive and intertriginous skin, and the company markets it as the leading branded topical across those three inflammatory skin conditions combined.
The investment picture is a classic single-franchise growth story reaching an inflection. ZORYVE net product sales grew to about $372 million in 2025, up roughly 123% year over year, and Arcutis posted its first profitable quarter in Q4 2025 with positive operating cash flow before guiding 2026 revenue to roughly $480 to $495 million. Because nearly all revenue comes from one molecule, the stock is highly sensitive to prescription momentum, payer coverage, gross-to-net pricing dynamics, and new-indication approvals (including pediatric and infant atopic dermatitis expansions). Profitability is not yet consistent: Q1 2026 slipped back to a loss of about $11 million on seasonal patterns and reinvestment, then Q2 2026 swung back to net income of about $15 million on revenue of roughly $130 million, up about 59% year over year, with EPS of $0.11 against a $0.05 estimate. Q3 2026 revenue rose to about $144 million, up roughly 45% year over year, but net income fell to about $8.8 million and EPS of $0.06 missed the $0.17 consensus. Management raised 2026 revenue guidance to $535 to $545 million and generated about $19 million of operating cash flow in the quarter. TTM revenue is now about $509 million and TTM net income about $30 million. The company still carries a large accumulated deficit from its pre-commercial years, so results can stay volatile even as the top line compounds.
As of November 20, 2026 ARQT closed at $26.64, down about 8.1% year to date and 2.5% over the past year, within a 52-week range of $19.30 to $34.80, and about 15% lower over the past month after the third-quarter EPS miss. The FDA's decision on extending ZORYVE cream 0.05% to infants aged 3 months and older with atopic dermatitis is expected by February 23, 2027, supported by phase 2 data in 101 infants presented in October and caregiver-reported outcomes presented in November 2026. In November Arcutis also began enrolling a phase 3 study of ZORYVE cream 0.3% in moderate to severe atopic dermatitis, and it expects phase 2 proof-of-concept readouts in vitiligo in Q4 2026 and hidradenitis suppurativa in Q1 2027. Analysts expect Q4 2026 EPS of about $0.20 on revenue near $163 million.
What's driving Arcutis Biotherapeutics, Inc. (ARQT)?
1. Multi-indication ZORYVE expansion
ZORYVE has moved from a single plaque-psoriasis cream to a franchise spanning psoriasis, seborrheic dermatitis, and atopic dermatitis across creams and a foam. Each new FDA-approved indication and each step down in age widens the addressable prescriber base off one familiar molecule. The next step is infants: a phase 2 study of the 0.05% cream in 101 children aged 3 to under 24 months showed rapid clearance over four weeks with no serious adverse events, and an FDA decision is expected by February 23, 2027. This multi-indication strategy is the core engine behind revenue growth of about 59% in Q2 2026 and about 45% in Q3, which management described as demand-driven across all formulations. A phase 3 study of the 0.3% cream in moderate to severe atopic dermatitis began enrolling in November 2026, aimed at a more severe patient group than current labels cover.
2. Revenue growth reaching profitability
Net product sales grew to about $372 million in 2025 (total revenue about $376 million), and the company reported net income of roughly $17 million in Q4 2025 with positive operating cash flow, its first profitable quarter. After a Q1 2026 loss, Q2 2026 returned to net income of about $15 million, and Q3 stayed profitable at about $8.8 million despite missing EPS estimates. TTM operating margin is about 7%. Management raised 2026 revenue guidance to $535 to $545 million (it began the year at roughly $480 to $495 million) and expects to stay cash flow positive through year-end; analysts model about $703 million of revenue in 2027 with EPS near $1.09. Reaching self-funded profitability would reduce reliance on dilutive financing and end the cash-burning launch phase.
3. Payer coverage and prescriber reach
A large part of the growth has come from expanding commercial and Medicare coverage plus an enlarged dermatology sales force targeting higher-volume prescribers. Broader formulary access lowers patient out-of-pocket cost and improves the gross-to-net economics that turn prescriptions into recognized revenue. Continued coverage wins and better prescriber call frequency are key levers for converting demand into reported sales.
4. Pipeline and label depth
Beyond current approvals, Arcutis is pursuing further ZORYVE label expansions (younger pediatric psoriasis, infant atopic dermatitis, and moderate to severe atopic dermatitis with the 0.3% cream) and testing roflumilast in new diseases, with phase 2 proof-of-concept readouts expected in vitiligo in Q4 2026 and hidradenitis suppurativa in Q1 2027. Guideline recommendations from dermatology bodies support adoption. This gives the franchise a longer runway, though the pipeline remains concentrated around a single mechanism rather than a broadly diversified portfolio.
What are the risks to Arcutis Biotherapeutics, Inc. (ARQT)?
The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. Profitability is early and inconsistent, with Q1 2026 returning to a loss of about $11 million on seasonality and reinvestment before Q2 recovered, and Q3 net income of about $8.8 million fell short of estimates as spending grew faster than revenue, and the business carries a large accumulated deficit built up over its pre-commercial years. Competition is real, including Incyte's Opzelura (a JAK-inhibitor cream), Dermavant's Vtama (tapinarof), generic topical steroids, and systemic biologics like Dupixent in atopic dermatitis. Gross-to-net adjustments, rebates, and inventory timing can make quarterly revenue lumpy, and continued sales-force and marketing spend can keep operating results volatile even as demand grows. Valuation now assumes that growth continues: the stock trades near 6.6 times sales and about 24 times forward earnings, and an insider sale of about $1.4 million was disclosed in November 2026, and the infant label still depends on an FDA decision expected by February 23, 2027.
What is the Arcutis Biotherapeutics, Inc. (ARQT) forecast?
8 analysts publish price targets on ARQT, averaging $40.38 as of November 2026, or +53.2% against the $26.36 share price on November 20, 2026. The published targets run from $34.00 to $48.00, a moderate spread, and the ratings split 7 buy, 1 hold, 0 sell. Over the last six months there have been 5 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full ARQT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is ARQT a buy or a sell?
We give no verdict on Arcutis Biotherapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Multi-indication ZORYVE expansion. ZORYVE has moved from a single plaque-psoriasis cream to a franchise spanning psoriasis, seborrheic dermatitis, and atopic dermatitis across creams and a foam. The most optimistic published target, $48.00, assumes this works close to its best case.
The case against. The dominant risk is single-product concentration: nearly all revenue depends on ZORYVE, so any slowdown in prescriptions, an unfavorable payer or pricing shift, a safety signal, or eventual generic and patent challenges would hit the whole company. The most pessimistic target, $34.00, is roughly what ARQT is worth if this bites instead.
Read the full bull and bear case on ARQT, including what would have to change to break either one. Walnut is not an investment adviser.
Has Arcutis Biotherapeutics, Inc. (ARQT) split its stock?
No. Arcutis Biotherapeutics, Inc. (ARQT) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Arcutis Biotherapeutics, Inc. (ARQT) valued?
Market cap, P/E and dividend yield at today's price are in the ARQT key stats above. The business figures below come from Arcutis Biotherapeutics, Inc.'s reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$509 million
- Revenue growth (Q3 2026, year over year): ~45%
- Q3 2026 net income: ~$8.8 million (EPS $0.06 vs $0.17 est.)
- 2026 revenue guidance: $535 to $545 million (raised)
- Gross / operating margin (TTM): ~91% / ~7%
- Cash / debt: ~$259 million / ~$124 million
As of November 2026: As of November 2026, Arcutis trades at about 6.6 times TTM sales and roughly 121 times trailing earnings, a multiple that only makes sense against forward estimates (about 24 times), since earnings are just turning positive. Analysts expect 2026 EPS of about $0.33, down from $0.43 before the Q3 miss, rising to about $1.09 in 2027 on revenue near $703 million, so the valuation leans on ZORYVE's revenue trajectory and on spending growing more slowly than sales. The eight analysts Yahoo Finance tracks have a mean target near $40.
Who competes with Arcutis Biotherapeutics, Inc. (ARQT)?
Branded topical dermatology drugs
The most direct competitors are other novel non-steroidal topicals for inflammatory skin disease, notably Incyte's Opzelura (ruxolitinib, a JAK-inhibitor cream) and Dermavant's Vtama (tapinarof, an AhR agonist). These compete with ZORYVE for the same dermatologist prescriptions in atopic dermatitis and psoriasis, differing on dosing, label breadth, safety warnings, and price.
Generic topicals and systemic biologics
Low-cost generic topical corticosteroids and calcineurin inhibitors remain the default first-line therapy and a constant pricing and access headwind. For more severe disease, systemic biologics such as Sanofi and Regeneron's Dupixent set the treatment ceiling in atopic dermatitis, so ZORYVE competes to hold the mild-to-moderate topical segment.
Diversified dermatology and specialty pharma
Larger dermatology-focused companies (for example Incyte and other specialty pharma with multi-product portfolios) carry more diversified revenue and deeper commercial infrastructure. Compared with them, Arcutis offers concentrated exposure to one fast-growing franchise, which raises both the upside and the single-product risk relative to a broader peer.
What stocks are similar to Arcutis Biotherapeutics, Inc. (ARQT)?
Other names that sit close to ARQT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Arcutis Biotherapeutics, Inc. (ARQT)
There are three common ways to get ARQT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ARQT sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where ARQT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Arcutis Biotherapeutics, Inc. (ARQT)
Arcutis is a single-product dermatology growth story where ZORYVE's rapid, multi-indication expansion is pushing the company toward sustained profitability, so the stock tends to trade on prescription trends and label expansions rather than on a diversified earnings base. Q3 2026 showed the split: revenue grew about 45% and guidance went up, but EPS of $0.06 missed the $0.17 estimate and the shares fell about 15% over the past month. The next marker is the FDA decision on the infant atopic dermatitis label, expected by February 23, 2027.
More on Arcutis Biotherapeutics, Inc. (ARQT)
Whether ARQT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ARQT a buy or a sell?, and where the stock could go from here in the ARQT stock forecast.
For income investors, whether ARQT pays a dividend and how the payout looks is covered in does ARQT pay a dividend? And to weigh ARQT against a peer, read the full side-by-side comparisons: ARQT vs INCY and ARQT vs SNY.
Wondering how ARQT fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Arcutis Biotherapeutics, Inc.
Ask Walnut's AI anything about ARQT and see how it fits what you own.
FAQ
What does Arcutis Biotherapeutics do?
+
Arcutis is a commercial-stage medical dermatology company. Its business centers on ZORYVE, a topical roflumilast (PDE4 inhibitor) sold as creams and a foam approved for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis across a range of ages.
What is ZORYVE and why does it matter to ARQT?
+
ZORYVE is Arcutis's flagship product and the source of essentially all its revenue. It is a steroid-free, once-daily topical PDE4 inhibitor that the company markets as the leading branded topical across three inflammatory skin conditions, so ARQT's results track ZORYVE prescriptions closely.
Is Arcutis profitable?
+
Arcutis reached its first profitable quarter in Q4 2025 (about $17 million net income) with positive operating cash flow, but it still reported a net loss of about $16 million for full-year 2025 and slipped back to a loss of about $11 million in Q1 2026. Q2 2026 returned to net income of about $15 million and Q3 to about $8.8 million, and TTM net income is about $30 million. Profitability is at an early inflection rather than consistently established.
How fast is Arcutis growing?
+
ZORYVE net sales grew to roughly $372 million in 2025, up about 123% year over year, Q2 2026 revenue of about $130 million was up roughly 59%, and Q3 2026 revenue of about $144 million was up about 45%. TTM revenue is about $509 million, and management raised 2026 guidance to $535 to $545 million. Growth has been driven by new indications, broader age labels, and expanding payer coverage.
Who are Arcutis's main competitors?
+
Direct competitors include Incyte's Opzelura (a JAK-inhibitor cream) and Dermavant's Vtama (tapinarof). ZORYVE also competes with generic topical steroids as first-line therapy and, for severe disease, with systemic biologics like Dupixent in atopic dermatitis.
What are the biggest risks with ARQT?
+
The largest risk is dependence on a single product, ZORYVE, so any prescription slowdown, pricing or coverage shift, safety signal, or eventual generic competition would affect the whole company. Profitability is early and inconsistent, and quarterly revenue can be lumpy due to gross-to-net and seasonal factors.
How can I invest in Arcutis stock?
+
ARQT trades on the Nasdaq, so you can buy shares or fractional shares through any major brokerage, or hold it as one position inside a thematic dermatology or growth-biotech basket. It may also appear in some small-cap or biotech ETFs.
Does Arcutis pay a dividend?
+
No. Arcutis does not pay a dividend. Like most growth-stage biopharma companies, it reinvests cash into its commercial expansion, sales force, and pipeline, so any return would come from share-price changes rather than income.
How did Arcutis do in its latest quarter?
+
In Q3 2026, reported in early November, Arcutis posted revenue of about $144 million, up roughly 45% year over year, and net income of about $8.8 million, or $0.06 per share against a $0.17 consensus. It raised 2026 revenue guidance to $535 to $545 million and reported about $19 million of operating cash flow. Analysts expect Q4 2026 EPS of about $0.20 on revenue near $163 million.
How has ARQT stock performed in 2026?
+
As of November 20, 2026 ARQT closed at $26.64, down about 8.1% year to date and 2.5% over the past year, and about 15% lower over the last month after the Q3 EPS miss. The 52-week range is $19.30 to $34.80, and the eight analysts Yahoo Finance tracks have a mean price target near $40.
Is ZORYVE being approved for infants?
+
Arcutis has asked the FDA to extend ZORYVE cream 0.05% to infants with atopic dermatitis down to 3 months of age, with a decision expected by February 23, 2027. In October 2026 it presented phase 2 data in 101 infants aged 3 to under 24 months showing rapid disease clearance over four weeks and no serious adverse events, and in November it presented caregiver-reported outcomes from the same program at the ACAAI annual meeting.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Arcutis Biotherapeutics, Inc.'s investor relations page or your broker before making investment decisions.